Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
Mylène Fefeu, Michael Blatzer, Anita Kneppers, David Briand, Pierre Rocheteau, Alexandre Haroche, David Hardy, Mélanie Juchet-Martin, Anne Danckaert, François Coudoré, Abdulkarim Tutakhail, Corinne Huchet, Aude Lafoux, Rémi Mounier, Olivier Mir, Raphaël Gaillard, Fabrice Chrétie. Serotonin reuptake inhibitors improve muscle stem cell function and muscle regeneration in male mice. Nature communications. vol 15. issue 1. 2024-07-31. PMID:39085209. |
serotonin reuptake inhibitor antidepressants such as fluoxetine are widely used to treat mood disorders. |
2024-07-31 |
2024-08-03 |
mouse |
Katelyn Desorcy-Scherer, Ibrahim Zuniga-Chaves, Maggie A Reisner, Garret Suen, Laura L Hernande. Investigating the influence of perinatal fluoxetine exposure on murine gut microbial communities during pregnancy and lactation. Scientific reports. vol 14. issue 1. 2024-06-14. PMID:38877103. |
selective serotonin reuptake inhibitor (ssri) therapy is common among perinatal populations for the treatment of mood disorders. |
2024-06-14 |
2024-06-17 |
mouse |
Mai M Anwar, Ibrahim M Ibrahim Lail. The ameliorating effect of Rutin on hepatotoxicity and inflammation induced by the daily administration of vortioxetine in rats. BMC complementary medicine and therapies. vol 24. issue 1. 2024-04-08. PMID:38581023. |
vortioxetine (vortx) is a potent and selective type of selective serotonin reuptake inhibitor (ssri) that is mainly prescribed for treating major depression along with mood disorders as the first drug of choice. |
2024-04-08 |
2024-04-10 |
rat |
Rossella Cirillo, Sandra Duperrier, Pathik Parekh, Mathilde Millot, Qin Li, Marie-Laure Thiolat, Micaela Morelli, Jing Xie, Didier Le Bars, Jérôme Redouté, Erwan Bezard, Véronique Sgambat. Striatal Serotonin 4 Receptor is Increased in Experimental Parkinsonism and Dyskinesia. Journal of Parkinson's disease. 2024-02-10. PMID:38339940. |
alterations of serotonin type 4 receptor levels are linked to mood disorders and cognitive deficits in several conditions. |
2024-02-10 |
2024-02-12 |
rat |
V Sreeja, Anju Jose, Shashikant Patel, Bindu Menon, K V Athira, Sumana Chakravart. Pharmacogenetics of selective serotonin reuptake inhibitors (SSRI): A serotonin reuptake transporter (SERT)-based approach. Neurochemistry international. 2023-12-29. PMID:38157886. |
serotonin and its transporter is a prominent paradigm in mood disorders. |
2023-12-29 |
2024-01-05 |
Not clear |
Katelyn Desorcy-Scherer, Hannah P Fricke, Laura L Hernande. Selective serotonin reuptake inhibitors during pregnancy and lactation: A scoping review of effects on the maternal and infant gut microbiome. Developmental psychobiology. vol 66. issue 1. 2023-12-22. PMID:38131241. |
perinatal mood disorders are a tremendous burden to childbearing families and treatment with selective serotonin reuptake inhibitor (ssri) antidepressants is increasingly common. |
2023-12-22 |
2023-12-24 |
human |
Alexey Sarapultsev, Evgenii Gusev, Maria Komelkova, Irina Utepova, Shanshan Luo, Desheng H. JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions. Molecular biomedicine. vol 4. issue 1. 2023-11-08. PMID:37938494. |
furthermore, the influence of the pathway on serotonin receptors and phospholipase c has implications for stress and mood disorders. |
2023-11-08 |
2023-11-20 |
human |
Marcin Sochal, Alicja Witkowska, Agata Binienda, Agata Gabryelska, Piotr Białasiewicz, Jakub Fichna, Renata Talar-Wojnarowska, Ewa Małecka-Wojciesk. The Effect of Serotonin Transmission on Depressive and Insomnia Symptoms in Inflammatory Bowel Diseases. Journal of clinical medicine. vol 12. issue 19. 2023-10-14. PMID:37834999. |
the aim of this study was to investigate the relationship between 5-ht, the serotonin transporter (sert), and the clinical course of the disease with the occurrence of sleep and mood disorders. |
2023-10-14 |
2023-10-15 |
human |
Amni Al-Kachak, Sasha L Fulton, Giuseppina Di Salvo, Jennifer C Chan, Lorna A Farrelly, Ashley E Lepack, Ryan M Bastle, Lingchun Kong, Flurin Cathomas, Emily L Newman, Caroline Menard, Aarthi Ramakrishnan, Polina Safovich, Yang Lyu, Herbert E Covington, Li Shen, Kelly Gleason, Carol A Tamminga, Scott J Russo, Ian Maz. Histone H3 serotonylation dynamics in dorsal raphe nucleus contribute to stress- and antidepressant-mediated gene expression and behavior. bioRxiv : the preprint server for biology. 2023-09-26. PMID:37205414. |
serotonin-associated antidepressants (ads) remain the first line of therapy for many with depressive symptoms, yet low remission rates and delays between treatment and symptomatic alleviation have prompted skepticism regarding precise roles for serotonin in the precipitation of mood disorders. |
2023-09-26 |
2023-10-07 |
Not clear |
Doaa Ghorab, Ejlal M Abu-El-Rub, Mohamed Hamdi Gharaibeh, Alaa Yehya, Ramada R Khasawneh, Laila M Matalqah, Ahmed Mohamed Helal. Neurological Effects of Combining Low Toxic Dose of Tramadol and Nicotine: An Animal Model Evidence of Endoplasmic Reticulum Stress. BioMed research international. vol 2023. 2023-08-18. PMID:37593523. |
serotonin receptor blockers such as olanzapine may increase systemic serotonin levels and need further investigation to utterly pinpoint their roles in managing mood disorders. |
2023-08-18 |
2023-09-07 |
rat |
Katsiaryna Vashkevich, Kathryn Janiuk, Nasim Malek. A model for irritable bowel syndrome and anxiety comorbidities in relation to alcohol use disorders. Frontiers in medicine. vol 10. 2023-06-09. PMID:37293305. |
lack of sufficient serotonin levels is thought to play a key role in mood disorders, including anxiety disorders. |
2023-06-09 |
2023-08-14 |
human |
Afaf Albalaw. Deep venous thrombosis and hyponatremia associated with citalopram use for behavioral symptoms in Parkinson's disease: a case report. BMC geriatrics. vol 23. issue 1. 2023-06-01. PMID:37264337. |
selective serotonin reuptake inhibitors (ssris) are widely used for mood disorders and behavioral symptoms in older adults with cognitive impairment, but they have limited efficacy in patients with pdd. |
2023-06-01 |
2023-08-14 |
Not clear |
Angharad N de Cates, Marieke A G Martens, Lucy C Wright, Daisy Gibson, Gershon Spitz, Cassandra D Gould van Praag, Sana Suri, Philip J Cowen, Susannah E Murphy, Catherine J Harme. 5-HT Biological psychiatry. Cognitive neuroscience and neuroimaging. 2023-04-25. PMID:37098409. |
5-ht cognitive deficits are often comorbid with mood disorders, and can cause significant functional impairment even after resolution of the primary mood symptoms. |
2023-04-25 |
2023-08-14 |
Not clear |
Bence Bruncsics, Gabor Hullam, Bence Bolgar, Peter Petschner, Andras Millinghoffer, Kinga Gecse, Nora Eszlari, Xenia Gonda, Debra J Jones, Sorrel T Burden, Peter Antal, Bill Deakin, Gyorgy Bagdy, Gabriella Juhas. Genetic risk of depression is different in subgroups of dietary ratio of tryptophan to large neutral amino acids. Scientific reports. vol 13. issue 1. 2023-03-27. PMID:36973313. |
our results confirm the relevance of the serotonin hypothesis in understanding the neurobiological background of depression and highlight the importance of understanding its differential role in the context of environmental variables such as complexity of diet in influencing mental health, pointing towards emerging possibilities of personalised prevention and intervention in mood disorders in those who are genetically vulnerable. |
2023-03-27 |
2023-08-14 |
Not clear |
D E Alcantara-Zapata, N Lucero, N De Gregorio, P Astudillo Cornejo, C Ibarra Villanueva, M J Baltodano-Calle, G F Gonzales, C Beh. Women's mood at high altitude. sexual dimorphism in hypoxic stress modulation by the tryptophan-melatonin axis. Frontiers in physiology. vol 13. 2023-02-03. PMID:36733695. |
hypoxia and insomnia reduce serotonin (5-ht) availability; the latter defect being expressed as failure of brown adipose tissue (bat) activation and mood disorders. |
2023-02-03 |
2023-08-14 |
human |
Graziano Pinn. Biomarkers and treatments for mood disorders encompassing the neurosteroid and endocannabinoid systems. Journal of neuroendocrinology. 2023-01-10. PMID:36625096. |
while several biomarker candidates have been proposed for mood disorders, none has been implemented in clinical practice and the treatment still relies in the prescription of selective serotonin reuptake inhibitors that shows mixed efficacy and significant side effects. |
2023-01-10 |
2023-08-14 |
Not clear |
Hugo Martin, Sébastien Bullich, Maud Martinat, Mathilde Chataigner, Mathieu Di Miceli, Vincent Simon, Samantha Clark, Jasmine Butler, Mareike Schell, Simran Chopra, Francis Chaouloff, Andre Kleinridders, Daniela Cota, Philippe De Deurwaerdere, Luc Pénicaud, Sophie Layé, Bruno P Guiard, Xavier Fioramont. Insulin modulates emotional behavior through a serotonin-dependent mechanism. Molecular psychiatry. 2022-10-07. PMID:36207585. |
here we hypothesized that insulin modulates the serotonergic (5-ht) system to control emotional behavior and that insulin resistance in 5-ht neurons contributes to the development of mood disorders in t2d. |
2022-10-07 |
2023-08-14 |
Not clear |
Lourdes M DelRosso, Maria P Mogavero, Amy Fickensher, Oliviero Bruni, Carlos H Schenck, Raffaele Ferr. Effects of bupropion and SSRI antidepressants on leg movement activity and chin muscle tone during sleep in adolescents. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2022-09-08. PMID:36073843. |
to evaluate the effects of bupropion on periodic limb movements during sleep (plms) and chin electromyography (emg) tone in children taking it for their mood disorder, compared to the effects of selective serotonin reuptake inhibitors (ssris) and of bupropion combined with ssris. |
2022-09-08 |
2023-08-14 |
Not clear |
Spiro P Pantazatos, Nadine M Melhem, David A Brent, Francesca Zanderigo, Elizabeth A Bartlett, Mohammad Lesanpezeshki, Ainsley Burke, Jeffrey M Miller, J John Man. Ventral prefrontal serotonin 1A receptor binding: a neural marker of vulnerability for mood disorder and suicidal behavior? Molecular psychiatry. 2022-06-27. PMID:35760877. |
ventral prefrontal serotonin 1a receptor binding: a neural marker of vulnerability for mood disorder and suicidal behavior? |
2022-06-27 |
2023-08-14 |
Not clear |
Spiro P Pantazatos, Nadine M Melhem, David A Brent, Francesca Zanderigo, Elizabeth A Bartlett, Mohammad Lesanpezeshki, Ainsley Burke, Jeffrey M Miller, J John Man. Ventral prefrontal serotonin 1A receptor binding: a neural marker of vulnerability for mood disorder and suicidal behavior? Molecular psychiatry. 2022-06-27. PMID:35760877. |
mood disorders and suicidal behavior have moderate heritability and are associated with altered corticolimbic serotonin 1a receptor (5-ht |
2022-06-27 |
2023-08-14 |
Not clear |